JP5735804B2 - 発現ベクター - Google Patents

発現ベクター Download PDF

Info

Publication number
JP5735804B2
JP5735804B2 JP2010541633A JP2010541633A JP5735804B2 JP 5735804 B2 JP5735804 B2 JP 5735804B2 JP 2010541633 A JP2010541633 A JP 2010541633A JP 2010541633 A JP2010541633 A JP 2010541633A JP 5735804 B2 JP5735804 B2 JP 5735804B2
Authority
JP
Japan
Prior art keywords
plasmid
dna
bifidobacterium
gene
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010541633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517929A5 (enExample
JP2011517929A (ja
Inventor
裕子 嶋谷
裕子 嶋谷
瞳 清水
瞳 清水
弘美 米倉
弘美 米倉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaeropharma Science Inc
Original Assignee
Anaeropharma Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science Inc filed Critical Anaeropharma Science Inc
Publication of JP2011517929A publication Critical patent/JP2011517929A/ja
Publication of JP2011517929A5 publication Critical patent/JP2011517929A5/ja
Application granted granted Critical
Publication of JP5735804B2 publication Critical patent/JP5735804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010541633A 2008-04-17 2009-04-16 発現ベクター Active JP5735804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12452808P 2008-04-17 2008-04-17
US61/124,528 2008-04-17
PCT/JP2009/001768 WO2009128272A1 (en) 2008-04-17 2009-04-16 Expression vector

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014248772A Division JP6089025B2 (ja) 2008-04-17 2014-12-09 発現ベクター

Publications (3)

Publication Number Publication Date
JP2011517929A JP2011517929A (ja) 2011-06-23
JP2011517929A5 JP2011517929A5 (enExample) 2012-06-07
JP5735804B2 true JP5735804B2 (ja) 2015-06-17

Family

ID=40792658

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010541633A Active JP5735804B2 (ja) 2008-04-17 2009-04-16 発現ベクター
JP2010541634A Active JP5514735B2 (ja) 2008-04-17 2009-04-17 嫌気的疾患用治療薬
JP2014248772A Active JP6089025B2 (ja) 2008-04-17 2014-12-09 発現ベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010541634A Active JP5514735B2 (ja) 2008-04-17 2009-04-17 嫌気的疾患用治療薬
JP2014248772A Active JP6089025B2 (ja) 2008-04-17 2014-12-09 発現ベクター

Country Status (12)

Country Link
US (3) US8383398B2 (enExample)
EP (2) EP2274422B1 (enExample)
JP (3) JP5735804B2 (enExample)
KR (3) KR101674977B1 (enExample)
CN (2) CN102046791B (enExample)
CA (2) CA2721653C (enExample)
DK (2) DK2274422T3 (enExample)
ES (2) ES2628378T3 (enExample)
HU (2) HUE033561T2 (enExample)
PL (2) PL2274422T3 (enExample)
PT (2) PT2274422T (enExample)
WO (2) WO2009128272A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091243A (ja) * 2008-04-17 2015-05-14 株式会社アネロファーマ・サイエンス 発現ベクター

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535939B2 (en) 2010-01-29 2013-09-17 Anaeropharma Science, Inc. Transfection vector
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
WO2013008881A1 (ja) * 2011-07-13 2013-01-17 株式会社アネロファーマ・サイエンス 虚血性疾患治療薬
KR20170088866A (ko) 2014-12-03 2017-08-02 가부시키가이샤 아네로파마·사이엔스 공발현 플라스미드
KR101892722B1 (ko) * 2015-01-19 2018-08-28 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 허혈성 질환 치료제
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
WO2021038975A1 (ja) 2019-08-28 2021-03-04 株式会社アネロファーマ・サイエンス ダイアボディ型ＢｓＡｂを発現・分泌するビフィドバクテリウム属細菌
CN112999215B (zh) * 2019-12-20 2024-06-21 复旦大学 呋喃酮糖苷类化合物的应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用
WO2024187069A1 (en) * 2023-03-08 2024-09-12 University Of Florida Research Foundation, Incorporated Engineering enterobacteria to site-specifically activate the anticancer prodrug 5-fluorocytosine for treating colon cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713601D0 (en) * 1987-06-10 1987-07-15 Unilever Plc Fermentation
WO1991009131A1 (en) * 1989-12-20 1991-06-27 Valio Finnish Cooperative Dairies Association Cloning vector for use in lactic acid bacteria
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7008633B2 (en) * 2000-12-18 2006-03-07 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
KR100457879B1 (ko) * 2001-02-24 2004-11-18 주식회사 비피도 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법
PT2088193E (pt) 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
ES2548516T3 (es) * 2005-01-21 2015-10-19 The Research Foundation Of The State University Of New York Métodos para el tratamiento de la capsulitis adhesiva
EP1867714B1 (en) 2005-04-08 2013-09-18 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
CA2646244A1 (en) * 2006-03-27 2007-10-04 Government Of The United States Of Americas, As Represented By The Secre Tetracycline compounds and methods of treatment
GB2439310A (en) * 2006-04-13 2007-12-27 Ambrozea Inc Fermentation residuals from genetically-modified microorganisms
JP5048661B2 (ja) 2006-05-24 2012-10-17 株式会社アネロファーマ・サイエンス 遺伝子輸送担体作製方法
EP2274422B1 (en) * 2008-04-17 2017-03-15 Anaeropharma Science, Inc. Expression vector

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091243A (ja) * 2008-04-17 2015-05-14 株式会社アネロファーマ・サイエンス 発現ベクター

Also Published As

Publication number Publication date
CN102046190A (zh) 2011-05-04
EP2274422B1 (en) 2017-03-15
US20110110893A1 (en) 2011-05-12
KR20160102584A (ko) 2016-08-30
JP5514735B2 (ja) 2014-06-04
JP2011518112A (ja) 2011-06-23
EP2280717A1 (en) 2011-02-09
PT2280717T (pt) 2018-10-04
WO2009128275A9 (en) 2010-11-11
CA2721664A1 (en) 2009-10-22
CN102046791B (zh) 2013-09-18
CA2721653A1 (en) 2009-10-22
PT2274422T (pt) 2017-06-28
EP2274422A1 (en) 2011-01-19
CN102046791A (zh) 2011-05-04
JP6089025B2 (ja) 2017-03-01
US8470311B2 (en) 2013-06-25
ES2686080T3 (es) 2018-10-16
CA2721653C (en) 2018-03-20
CA2721664C (en) 2018-01-23
CN102046190B (zh) 2013-03-13
US20090264513A1 (en) 2009-10-22
WO2009128275A4 (en) 2010-02-18
JP2015091243A (ja) 2015-05-14
KR101674977B1 (ko) 2016-11-10
US20130122582A1 (en) 2013-05-16
DK2274422T3 (en) 2017-07-03
PL2280717T3 (pl) 2018-10-31
WO2009128272A1 (en) 2009-10-22
WO2009128275A1 (en) 2009-10-22
DK2280717T3 (en) 2018-09-10
KR20100134765A (ko) 2010-12-23
JP2011517929A (ja) 2011-06-23
PL2274422T3 (pl) 2017-09-29
EP2280717B1 (en) 2018-05-30
HUE039768T2 (hu) 2019-02-28
KR101671283B1 (ko) 2016-11-02
WO2009128272A4 (en) 2010-02-18
KR20110021784A (ko) 2011-03-04
US8383398B2 (en) 2013-02-26
WO2009128272A9 (en) 2010-11-11
HUE033561T2 (hu) 2017-12-28
ES2628378T3 (es) 2017-08-02

Similar Documents

Publication Publication Date Title
JP6089025B2 (ja) 発現ベクター
EP2910636B1 (en) Transformation plasmid
EP2019138A1 (en) Method of constructing gene transport support

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150417

R150 Certificate of patent or registration of utility model

Ref document number: 5735804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250